Veradermics Advances VDPHL01 in Phase 2/3 Clinical Trial for Female Pattern Hair Loss, Marking a Milestone in the Development of the Potential First-Ever Oral Prescription Treatment for Women
Veradermics, Incorporated, a dermatologist-founded, late clinical-stage biopharmaceutical company developing potentially first-in-class therapeutics for common dermatologic conditions, today announced it has begun enrolling women in its Phase 2/3 registration-directed clinical trial for its lead investigational product, VDPHL01, marking the first such trial for an oral treatment in female pattern hair loss. VDPHL01 is an extended-release oral minoxidil treatment with the potential to be the first non-hormonal oral treatment designed specifically for hair regrowth in women and men and the first-ever oral prescription treatment for women with pattern hair loss.
Veradermics Announces Oversubscribed $150 Million Series C Financing to Advance VDPHL01 Through Multiple Phase 3 Trials as Potentially the First Non-Hormonal Oral Therapeutic for Hair Regrowth in Women and Men
Veradermics, Incorporated (“Veradermics”), a dermatologist-founded, late clinical-stage biopharmaceutical company developing potentially first-in-class therapeutics for common dermatologic conditions, announced today the completion of an oversubscribed $150 million Series C financing. The financing was designed to support the registrational development and planned New Drug Application (“NDA”) submission for Veradermics’ lead investigational product, VDPHL01, the potential first and only extended-release oral minoxidil treatment designed specifically for hair regrowth in women and men. Veradermics also announced preliminary data from the male cohort from its ongoing Phase 2 trial studying VDPHL01 for the treatment of pattern hair loss in women and men.
Veradermics Raises $75 Million in Series B Financing and Initiates Phase 2/3 Trial for Hair Loss
Veradermics, a late clinical-stage aesthetics and dermatology-focused biopharmaceutical company developing first-in-class therapeutics for common dermatologic conditions, announced today the closing of a $75 million Series B financing. The financing was led by Suvretta Capital Management and included new investors Longitude Capital, Surveyor Capital (a Citadel company), Osage University Partners, and PhiFund. Existing investors, JW Childs Associates, Connecticut Innovations, and Vlad Coric, MD, also participated in this round. In connection with this financing, Amanda Birdsey-Benson, PhD from Suvretta Capital Management and Patrick Enright from Longitude Capital will join the Veradermics Board of Directors.
